WebDoctor Encyclopedia

Oesophagus

Oesophageal squamous cell carcinoma

Oesophageal squamous cell carcinoma arises from the squamous lining, often mid/upper oesophagus. This entry covers smoking, alcohol, and chemoradiation.

Medically reviewed Last reviewed November 15, 2026

Overview

Oesophageal squamous cell carcinoma (OSCC) is a malignant epithelial tumour originating from the squamous cells lining the oesophagus. It remains the predominant histological subtype of oesophageal cancer globally, particularly in the “Asian Oesophageal Cancer Belt” stretching from Northern Iran through Central Asia to Northern China. While adenocarcinoma has surpassed squamous cell carcinoma in incidence in many Western nations due to rising rates of obesity and gastro-oesophageal reflux disease (GORD), OSCC continues to represent a significant global health burden, accounting for approximately 90% of all oesophageal cancer cases worldwide.

OSCC is characterised by an aggressive biological behaviour, a propensity for early lymphatic spread, and a frequently advanced stage at diagnosis. Despite advances in multimodal therapy, the overall 5-year survival rate remains poor, ranging from 15% to 25% in most population-based studies. Early detection through endoscopic screening in high-risk populations and the application of neoadjuvant therapy for locally advanced disease represent the most impactful strategies for improving outcomes.

Epidemiology and Risk Factors

Global Distribution

The geographical variation in OSCC incidence is among the most extreme for any malignancy, with a 100-fold difference between high- and low-risk areas.

  • High-Risk Areas: The “Asian Belt” (Northern China, Kazakhstan, Northern Iran, Mongolia), Eastern Africa (Malawi, Kenya), and parts of South America (Southern Brazil).
  • Low-Risk Areas: Western Europe, North America, Oceania, and Western Africa.
  • Sex Disparity: Historically, OSCC affects men 3–4 times more frequently than women, though this gap narrows in high-risk regions where environmental carcinogens affect both sexes equally.
  • Age: Peak incidence occurs in the 6th and 7th decades of life; diagnosis before age 40 is rare but increasing in some populations.

Established Risk Factors

Risk Factor Category Specific Factors Mechanism of Action Relative Risk Magnitude
Chemical Carcinogens Tobacco (cigarettes, bidis, pipes), Alcohol (ethanol, acetaldehyde) Synergistic DNA damage; acetaldehyde is a Group 1 carcinogen causing DNA adducts and cross-links. Very High (Synergistic: RR 10–100x for heavy users of both)
Thermal Injury Consumption of very hot beverages (>60°C/140°F) Chronic mucosal inflammation, impaired barrier function, promotion of cell turnover. High (IARC Group 2A: “Probably carcinogenic”)
Nutritional Deficiencies Low intake of fresh fruits/vegetables (Vitamins A, C, E, folate, selenium, zinc) Reduced antioxidant capacity, impaired DNA repair, immune dysfunction. Moderate-High
Chemical Contaminants N-nitroso compounds (pickled vegetables, preserved meats), Mycotoxins (Fusarium toxins in maize/wheat), Polycyclic Aromatic Hydrocarbons (indoor air pollution, opium) Direct DNA alkylation and mutagenicity. High in endemic areas
Pre-malignant Conditions Achalasia (stasis/esophagitis), Tylosis (hereditary), Plummer-Vinson Syndrome (iron deficiency webs), Lye Stricture (corrosive injury), Radiation Oesophagitis Chronic inflammation, metaplasia, dysplasia progression. Very High (Relative risk 16–280x depending on condition)
Infectious Agents Human Papillomavirus (HPV) (Types 16, 18) E6/E7 oncoprotein degradation of p53 and Rb tumour suppressors. Debated/Moderate (Strong geographic variation; high in China/South Africa, low in West)
Lifestyle/Metabolic Obesity (paradoxically inverse association vs adenocarcinoma), Low socioeconomic status Marker for nutritional deficiency, poor oral hygiene, environmental exposure. Moderate

The synergistic interaction between tobacco and alcohol is multiplicative, not merely additive. A heavy smoker (>20 cigarettes/day) and heavy drinker (>100g ethanol/day) has a relative risk exceeding 100 times that of a never-smoker/never-drinker.

Pathophysiology and Molecular Pathogenesis

OSCC develops through a well-defined multistep carcinogenic sequence:

Normal Squamous Epithelium → Basal Cell Hyperplasia → Low-Grade Dysplasia → High-Grade Dysplasia / Carcinoma in Situ (CIS) → Invasive Squamous Cell Carcinoma.

Molecular Drivers

Unlike oesophageal adenocarcinoma (driven by TP53, CDKN2A, SMAD4, ARID1A alterations in the context of Barrett’s metaplasia), OSCC exhibits a distinct mutational landscape:

  1. TP53 Mutations: Present in >90% of invasive OSCCs, often occurring early in the dysplasia-carcinoma sequence. Loss of p53 function abrogates apoptosis and cell-cycle checkpoints.
  2. Cell Cycle Deregulation: CDKN2A (p16) inactivation via mutation, deletion, or promoter methylation is frequent. CCND1 (Cyclin D1) amplification drives G1/S transition.
  3. Receptor Tyrosine Kinase Pathways: EGFR amplification/overexpression (30–60%), ERBB2 (HER2) amplification (2–10%, lower than in adenocarcinoma), FGFR1 amplification.
  4. PI3K/AKT/mTOR Pathway: PIK3CA mutations (10–15%), PTEN loss.
  5. NOTCH1 Pathway: Inactivating mutations in NOTCH1 (10–20%), suggesting a tumour-suppressive role in squamous differentiation.
  6. Epigenetic Silencing: Global hypomethylation and promoter-specific hypermethylation (e.g., CDKN2A, MGMT, RUNX3) are hallmarks.

Field Cancerisation

A critical concept in OSCC is field cancerisation. The entire oesophageal mucosa (and often the aerodigestive tract) is exposed to carcinogens, resulting in widespread genetic and epigenetic alterations. This explains the high rates of:

  • Synchronous primary tumours (multiple tumours in the oesophagus at diagnosis).
  • Metachronous second primary tumours (new tumours developing years after curative treatment, often in the head, neck, or lung).
  • Local recurrence at the anastomotic site or residual mucosa.

Clinical Presentation

Symptoms

The clinical presentation of OSCC is largely dictated by the tumour’s size, location, and depth of invasion. Dysphagia is the cardinal symptom, but it is a late sign, typically appearing only when the luminal diameter is narrowed to <13–15 mm (normal ~20–25 mm).

Progressive Dysphagia (The Hallmark)

  • Stage 1 (Solids): Difficulty swallowing coarse, dry foods (bread, meat, raw vegetables). Patients unconsciously modify diet (chewing longer, avoiding trigger foods).
  • Stage 2 (Soft Solids): Inability to swallow soft foods (mashed potato, banana, scrambled egg).
  • Stage 3 (Liquids): Inability to swallow water or saliva. This indicates near-complete luminal obstruction.
  • Odynophagia: Painful swallowing, often retrosternal or epigastric, suggesting ulceration or mediastinal invasion.

Weight Loss and Nutritional Decline

  • Significant unintentional weight loss (>10% body weight in 3–6 months) is present in 50–80% of patients at diagnosis.
  • Results from reduced caloric intake, cancer cachexia (cytokine-driven hypermetabolism), and malabsorption.

Respiratory and Aerodigestive Symptoms

  • Coughing/Choking on swallowing: Suggests tracheo-oesophageal fistula (TOF) formation due to local invasion into the trachea or main bronchi. This is a catastrophic complication.
  • Hoarseness (Dysphonia): Indicates involvement of the recurrent laryngeal nerve (RLN), usually the left RLN which loops under the aortic arch. This signifies advanced (T4) disease and unresectability in many contexts.
  • Aspiration Pneumonia: Recurrent lower respiratory tract infections due to micro-aspiration or fistula.

Pain Syndromes

  • Retrosternal/Back Pain: Deep, boring pain suggests mediastinal invasion (aorta, vertebral bodies).
  • Ear Pain (Otalgia): Referred pain via the vagus nerve (Arnold’s nerve branch) or glossopharyngeal nerve.

Paraneoplastic Syndromes (Rare but Specific)

  • Hypertrophic Osteoarthropathy (Pierre-Marie-Bamberger syndrome): Clubbing, periostitis, arthritis.
  • Dermatomyositis/Polymyositis: Strong association with OSCC.
  • Acquired Acanthosis Nigricans: Velvety hyperpigmentation in axillae/groin (sign of gastric/oesophageal adenocarcinoma typically, but reported in SCC).

Physical Examination Findings

  • Supraclavicular Lymphadenopathy: Virchow’s node (Left supraclavicular / Troisier’s sign) indicates thoracic duct metastasis. Right supraclavicular nodes drain the mediastinum.
  • Cervical Lymphadenopathy: Scalene or deep cervical nodes (upper/middle third tumours).
  • Cachexia/Muscle Wasting: Temporal wasting, loss of subcutaneous fat.
  • Signs of Malnutrition: Glossitis, angular stomatitis, peripheral oedema (hypoalbuminemia).
  • Horner’s Syndrome: Ptosis, miosis, anhidrosis (invasion of sympathetic chain).

How Does It Look? (Endoscopic, Radiological, and Pathological Appearance)

This section details the visual phenotype of OSCC across diagnostic modalities.

1. Endoscopic Appearance (White Light Imaging – WLI)

The oesophagus is assessed systematically from the upper oesophageal sphincter (UES) to the gastro-oesophageal junction (GOJ). Tumour location is described by distance from the incisors (cm) and anatomical third (Upper: 15–24cm, Middle: 24–32cm, Lower: 32–40cm).

Macroscopic Type (Borrmann Classification Adapted for Oesophagus) Endoscopic Description Frequency Typical Stage Association
Type I: Polypoid / Fungating (Exophytic) Cauliflower-like mass protruding into lumen; irregular, friable surface; bleeds easily on contact. Often ulcerated on top. ~15–20% Often earlier (T1/T2) but can be bulky T3.
Type II: Ulcerative / Infiltrative Large, deep, irregular ulcer with raised, indurated (hard), rolled edges. Necrotic base (yellow-white slough). Surrounding mucosa may appear normal or inflamed. ~40–50% Locally advanced (T2/T3). High risk of perforation on biopsy.
Type III: Infiltrating / Stricture (Constrictive) Concentric, rigid, annular narrowing of the lumen (“napkin ring” or “apple core”). Mucosa proximal to stricture often dilated/retention saliva. Scope often cannot pass. ~30–40% Advanced (T3/T4). Longitudinal submucosal spread common.
Type IV: Superficial Spreading Flat or slightly elevated plaque; subtle colour change (redness, whitish discoloration); loss of vascular pattern. No mass effect. ~5–10% (Higher in screening) Early Cancer (T1a/T1b). Critical to detect.
Type 0 (Paris Classification) Subtypes for Early Cancer 0-Ip: Pedunculated polyp.<br>0-Is: Sessile polyp.<br>0-IIa: Slightly elevated.<br>0-IIb: Flat.<br>0-IIc: Slightly depressed.<br>0-III: Excavated (ulcerated). Screening detected T1a (Mucosa) or T1b (Submucosa).

Key Endoscopic Signs of Invasion Depth (Predicting T-Stage):

  • Mucosal (T1a): Lesion moves freely with insufflation; soft on palpation (if EUS probe used); distinct demarcation line (DL) visible with iodine staining.
  • Submucosal (T1b): “Submucosal tumour” look; harder consistency; convergence of folds; DL may be irregular.
  • Muscularis Propria / Adventitia (T2/T3): Fixed, rigid wall; loss of peristalsis; “shouldering” of ulcer edges; impossible to insufflate distal to tumour.
  • T4 Invasion: Visible invasion into trachea (fistula), aorta (pulsatile mass), or lung/pleura.

2. Advanced Imaging-Enhanced Endoscopy (Critical for “How it looks” in Early Detection)

Standard WLI misses up to 15–20% of early lesions. Image-Enhanced Endoscopy (IEE) is standard of care in high-volume centres.

Modality Principle OSCC Appearance (“The Look”) Clinical Utility
Lugol’s Chromoscopy (Iodine Staining) Glycogen in normal squamous epithelium stains dark brown/black. Dysplasia/Cancer lacks glycogen → Unstained (Mustard Yellow/Pink) areas. Demarcation Line (DL): Sharp border between stained (normal) and unstained (tumour).<br>Pink Colour Sign: Unstained area appears pink/red due to exposed vasculature.<br>Microvascular Pattern: Visible as fine red dots/loops in unstained zone. Gold standard for mapping extent. Defines resection margins for ESD/EMR. Detects synchronous lesions. False positives: inflammation, post-radiation.
Narrow Band Imaging (NBI) / BLI / LCI Optical filtering (Blue 415nm / Green 540nm) enhances haemoglobin absorption → visualises microvascular architecture and surface pattern. Intraepithelial Papillary Capillary Loops (IPCLs):<br>• Normal: Regular, fine, evenly spaced dots/loops (Type A).<br>• Low-grade Dysplasia: Slightly dilated, tortuous (Type B1).<br>• High-grade Dysplasia / CIS / T1a: Irregular, dilated, chaotic, corkscrew, angular loops (Type B2/B3).<br>• Deep Invasion (T1b+): Avessel areas, chaotic stellate vessels, loss of structure. Real-time “Optical Biopsy”. JES Classification (Japan Esophageal Society) / ESGE Criteria allow prediction of histology and depth without random biopsies.
Magnifying Endoscopy (ME-NBI) High magnification (80–150x) + NBI. Detailed Microvascular Pattern (MVP) and Microsurface Pattern (MSP – light blue crests). Highest accuracy for depth prediction (T1a vs T1b). Differentiates cancer from inflammation.

3. Radiological Appearance

Barium Swallow / Oesophagram (Historical Context / Initial Screening)

  • Early (T1): Small plaque, filling defect, “moth-eaten” mucosa, tiny ulcer niche (<5mm), subtle irregularity.
  • Advanced (T2/T3):
  • Irregular, rigid narrowing (“Rat-tail” or “String sign” for Type III).
  • Shouldering: Shelving of ulcer edges.
  • Ulcer niche: Deep, penetrating, irregular margins (Carman’s meniscus sign – usually malignant).
  • Mucosal destruction: “Moth-eaten” appearance.
  • T4 Signs: Tracheo-oesophageal fistula (contrast enters trachea/bronchi), Aorto-oesophageal fistula (rare, fatal), Mediastinal extravasation, loss of aortic knob/aortopulmonary window fat plane.

Computed Tomography (CT) Neck/Chest/Abdomen/Pelvis (Staging Standard)

  • Primary Tumour: Circumferential or eccentric wall thickening (>5–10mm). Heterogeneous enhancement (necrosis). Loss of normal fat planes between oesophagus and adjacent structures (trachea, aorta, left atrium, vertebra, lung) = T4.
  • Lymph Nodes: Short axis >10mm (mediastinum/hilum), >8mm (cervical/retropharyngeal), >10mm (coeliac/upper abdominal). Central necrosis suggests metastasis. PET-CT fusion improves specificity.
  • Distant Mets: Liver (hypodense lesions), Lung (nodules), Adrenals, Bone (lytic/sclerotic), Peritoneum/Ascites.

Endoscopic Ultrasound (EUS) – Best for T and N Staging (Local)

  • Layered Architecture (5 Layers):
  1. Superficial Mucosa (Hyperechoic)
  2. Deep Mucosa (Hypoechoic)
  3. Submucosa (Hyperechoic) <– Critical barrier
  4. Muscularis Propria (Hypoechoic)
  5. Adventitia (Hyperechoic)
  • T-Stage Look:
  • T1a: Tumour confined to Layers 1–2. Smooth outer margin.
  • T1b: Tumour invades Layer 3 (Submucosa). Depth measured in mm.
  • T2: Tumour invades Layer 4 (Muscularis Propria).
  • T3: Tumour invades Layer 5 (Adventitia) but fat plane preserved.
  • T4: Tumour breaches Layer 5; direct visualisation of invasion into aorta (loss of adventitia/aortic wall interface), trachea (air interface), vertebra, lung.
  • N-Stage Look: Hypoechoic, round/oval nodes with sharp margins, >10mm, central necrosis (FNA confirmation needed).

PET-CT (Fluorodeoxyglucose – FDG)

  • Primary: Intense focal FDG uptake (SUVmax often >10–15). Physiological uptake in normal oesophagus is low/absent.
  • Nodes: High sensitivity for nodal mets (detects metabolic activity in normal-sized nodes).
  • Distant Mets: Whole-body survey for occult M1 disease (bone, liver, distant nodes).
  • Post-Neoadjuvant: Deauville Score / PERCIST criteria used to assess metabolic response (complete metabolic response = good prognostic sign).

4. Histopathological Appearance (Microscopic “Look”)

Gross Pathology (Macroscopic):

  • Specimen received as oesophagectomy (cylindrical tube) or endoscopic resection (ESD/EMR) specimen (flattened, pinned).
  • Tumour: Grey-white, firm, gritty, irregular mass. Ulceration, necrosis, haemorrhage common.
  • Measurement: Longitudinal length, circumferential extent, distance to proximal/distal margins, distance to circumferential radial margin (CRM).

Microscopic Features (H&E Stain):

  • Architecture: Irregular nests, sheets, and cords of squamous cells invading through the basement membrane into submucosa/muscularis.
  • Cellular Features:
  • Polygonal cells with abundant eosinophilic (pink) cytoplasm (keratinization).
  • Intercellular bridges (desmosomes) – hallmark of squamous differentiation.
  • Keratin Pearls (concentric layers of keratinised cells) – well-differentiated.
  • Nuclei: Hyperchromatic, pleomorphic, prominent nucleoli, high mitotic activity (atypical mitoses).
  • Grading (WHO):
  • G1 (Well): >75% keratinisation, distinct intercellular bridges, pearls.
  • G2 (Moderate): 25–75% keratinisation.
  • G3 (Poor): <25% keratinisation; sheets of cells; bridges/pearls rare/focal. Requires IHC confirmation (p40/p63).
  • Stroma: Desmoplastic reaction (fibrosis), inflammatory infiltrate (tumour-infiltrating lymphocytes – TILs), tumour budding (single cells/small clusters at invasive front – poor prognosis).

Immunohistochemistry (IHC) Panel:

Marker Result in OSCC Utility
p40 / p63 Positive (Nuclear) Squamous lineage confirmation. p40 more specific than p63.
CK5/6 Positive (Cytoplasmic) Squamous differentiation marker.
CK7 / CK20 Usually CK7+/CK20- (Variable) Helps exclude metastasis from lung (CK7+/TTF1+) or GI adenocarcinoma (CK20+/CDX2+).
TTF-1 / Napsin A Negative Excludes lung primary.
CDX2 / SATB2 Negative Excludes colorectal/gastric adenocarcinoma.
GATA3 Negative Excludes urothelial/breast.
HER2 (ERBB2) IHC 3+ or FISH+ (Rare: 2–10%) Predictive for Trastuzumab (CheckMate 648 / KEYNOTE-811 protocols).
PD-L1 (CPS) Variable (CPS ≥1 or ≥10) Predictive for Pembrolizumab/Nivolumab (1st line metastatic / adjuvant CheckMate 577).
EBER-ISH Negative (usually) Excludes EBV-associated lymphoepithelioma-like carcinoma.

Staging Systems

Accurate staging dictates treatment. The AJCC 8th Edition (2017) / UICC TNM 8th Edition is the global standard. Note: Staging differs for SCC vs Adenocarcinoma.

TNM Definitions (Simplified)

T Category Definition
Tis High-grade dysplasia / Carcinoma in Situ (CIS) / Intraepithelial neoplasia (no invasion past basement membrane).
T1 Tumour invades lamina propria (T1a) or submucosa (T1b).
T2 Tumour invades muscularis propria.
T3 Tumour invades adventitia (outer connective tissue).
T4 Tumour invades adjacent structures:<br>• T4a: Resectable structures (pleura, pericardium, diaphragm, azygos vein).<br>• T4b: Unresectable structures (aorta, vertebral body, trachea/bronchus, heart).
N Category Definition
N0 No regional lymph node metastasis.
N1 Metastasis in 1–2 regional lymph nodes.
N2 Metastasis in 3–6 regional lymph nodes.
N3 Metastasis in ≥7 regional lymph nodes.
Regional Nodes: Cervical, Mediastinal (upper/mid/lower), Coeliac, Gastric (lesser curve), Para-oesophageal.
M Category Definition
M0 No distant metastasis.
M1 Distant metastasis (Liver, Lung, Bone, Non-regional nodes, Peritoneum).

Stage Grouping (OSCC Specific – AJCC 8th Ed)

Stage T N M Typical Treatment Approach
Stage 0 Tis N0 M0 Endoscopic Resection (ESD/EMR) or Ablation. Curative intent.
Stage IA T1a N0 M0 Endoscopic Resection (ESD preferred) if low risk (well/moderate diff, no LVI, <200µm SM invasion). Surgery (Oesophagectomy) if high risk or incomplete resection.
Stage IB T1b N0 M0 Surgery (Oesophagectomy) ± Lymphadenectomy. Debate on Neoadjuvant for T1bN0.
Stage IIA T2 N0 M0 Neoadjuvant Chemoradiotherapy (CROSS regimen) → Surgery (Standard). Definitive CRT if inoperable.
Stage IIB T1–T2 N1 M0 Neoadjuvant CRT → Surgery (Standard). Definitive CRT if inoperable.
Stage IIIA T3 N0–N1 M0 Neoadjuvant CRT → Surgery (Standard). Definitive CRT if T4a/N2 or inoperable.
Stage IIIB T1–T3 N2 M0 Definitive Chemoradiotherapy (Standard). Surgery considered in select responders (salvage).
T4a N0–N2 M0 Definitive CRT (Standard). Neoadjuvant CRT → Surgery in highly selected T4a (e.g. resectable pleural/pericardial invasion).
Stage IVA T4b Any N M0 Palliative Systemic Therapy (Chemo ± Immunotherapy). RT for symptom control.
Stage IVB Any T Any N M1 Palliative Systemic Therapy (Chemo ± Immunotherapy ± Targeted). Best Supportive Care.

Clinical Decision Point: The distinction between T1a (Mucosa) and T1b (Submucosa)** is the single most critical staging decision for early cancer, as it determines eligibility for organ-preserving endoscopic therapy vs. radical oesophagectomy with its attendant morbidity/mortality.

Diagnostic Workup Algorithm

  1. Index Suspicion: Dysphagia + Weight loss + Risk factors → Urgent Upper GI Endoscopy (Gastroscopy).
  2. Diagnostic Endoscopy:
  • High-definition White Light Imaging (HD-WLI).
  • Mandatory: Lugol’s Chromoscopy OR Virtual Chromoendoscopy (NBI/BLI/LCI) with Magnification.
  • Biopsies: Minimum 4–6 biopsies from lesion edges (avoid necrotic centre). Brush cytology adjunct.
  • Tattooing: Endoscopic marking (indigo carmine/spot) proximal/distal to lesion for surgical/endoscopic localisation.
  1. Pathology Confirmation: H&E + IHC (p40/p63) if poorly differentiated.
  2. Staging Investigations (Performed in Parallel):
  • Contrast-Enhanced CT Neck/Chest/Abdomen/Pelvis (Primary tumour extent, nodes, distant mets).
  • PET-CT (FDG) (Mandatory for Stage ≥IB / T1b+; detects occult mets in 10–15% changing management).
  • Endoscopic Ultrasound (EUS) + FNA (Gold standard for T-stage (early) and N-stage; mandatory for T1 assessment).
  • Bronchoscopy (Mandatory for Mid/Upper third tumours; assesses tracheobronchial invasion / rules out synchronous lung primary).
  • Nutritional Assessment: MUST score, Albumin, Pre-albumin, Trace elements. Prehabilitation referral.
  • Cardiopulmonary Fitness: CPET (VO2 max), Echo, PFTs (Assess fitness for surgery/CRT).
  • Dental Assessment: Mandatory before radiotherapy (prevent osteoradionecrosis).

Management Strategies

Treatment is stage-dependent, multidisciplinary (MDT), and patient-centred.

1. Endoscopic Therapy (Curative for Early Cancer: Tis, T1a, Select T1b)

  • Indications: Confined to mucosa (T1a) or superficial submucosa (T1b-SM1, <200µm / <500µm depending on guideline), Well/Mod differentiated, No Lymphovascular Invasion (LVI), Size <3–4cm (for EMR) / any size (for ESD), No nodal mets (EUS/PET negative).
  • Endoscopic Submucosal Dissection (ESD): Preferred for lesions >2cm, circumferential, or fibrotic. En-bloc R0 resection rate >90%. Allows accurate histological assessment of depth/LVI/margins.
  • Endoscopic Mucosal Resection (EMR): Cap-assisted or band ligation. For smaller (<2cm), protruding lesions. Piecemeal resection common for larger lesions → higher recurrence.
  • Adjuvant Ablation: Radiofrequency Ablation (RFA) or Argon Plasma Coagulation (APC) for residual flat dysplasia (field cancerisation) post-resection.
  • Surveillance: Intensive endoscopy (3, 6, 12, 18, 24 months, then annually) + Lugol’s/NBI. High risk of metachronous lesions (5–10%/year).

2. Surgery: Oesophagectomy (Curative for Resectable Locally Advanced: T1b-high risk – T4aN0-2)

  • Approaches:
  • Transthoracic (Ivor Lewis / McKeown / 3-Field): Right thoracotomy + Laparotomy ± Cervical incision. Standard for Mid/Upper tumours. Allows extensive 2-field (mediastinal+abdominal) or 3-field (add cervical) lymphadenectomy.
  • Transhiatal (Orringer): Laparotomy + Cervical incision. No thoracotomy. Lower pulmonary morbidity. Used for Lower third tumours, frail patients, or T4a invasion of aorta/trachea where thoracic dissection dangerous. Limited mediastinal lymphadenectomy.
  • Minimally Invasive (MIE / RAMIE): Thoracoscopic/Laparoscopic/Robotic. Standard of care in high-volume centres. Equivalent oncological outcomes, reduced pulmonary complications, faster recovery.
  • Reconstruction: Gastric Tube (Conduit) is standard (right gastroepiploic arcade). Alternatives: Colon interposition, Jejunal interposition (rare).
  • Lymphadenectomy: Minimum 15–20 nodes for accurate staging (AJCC). 2-field (Abdominal + Mediastinal) standard. 3-field (add Cervical) for Upper/Mid tumours (improves staging/regional control, increases RLN palsy risk).
  • Key Complications: Anastomotic Leak (10–15%), Pneumonia (20–30%), Recurrent Laryngeal Nerve Palsy (RLNP 10–30% transient, 2–5% permanent), Chylothorax, Atrial Fibrillation, Dumping Syndrome, Stricture.

3. Neoadjuvant Therapy (Standard for Stage II–III / T2+ or N+)

  • CROSS Regimen (Chemoradiotherapy – nCRT):
  • Radiotherapy: 41.4 Gy in 23 fractions (1.8 Gy/fx) to primary + regional nodes.
  • Chemotherapy: Carboplatin (AUC 2) + Paclitaxel (50 mg/m²) weekly x 5 cycles during RT.
  • Surgery: 4–6 weeks post-RT completion.
  • Evidence: CROSS Trial (NEJM 2012): Median OS 49.4 vs 24.0 months (HR 0.657). pCR rate ~29% (SCC 49%). Standard globally.
  • FLOT Regimen (Perioperative Chemotherapy – nCT):
  • Docetaxel + Oxaliplatin + 5-FU/Leucovorin (FLOT) x 4 cycles pre-op + 4 cycles post-op.
  • Evidence: FLOT4-AIO / ESOPEC Trials: FLOT non-inferior/superior to CROSS for SCC? Current guidelines (NCCN/ESMO) still favour CROSS (nCRT) for SCC due to higher pCR and local control; FLOT preferred for Adenocarcinoma. Check local MDT protocol.
  • Immunotherapy Integration (Emerging):
  • CheckMate 577 (Adjuvant Nivolumab): Post-nCRT + Surgery → Pathological residual disease (ypStage ≥I). DFS benefit (22.4 vs 11.0 mo). Standard Adjuvant for SCC with residual disease.
  • KEYNOTE-811 / CheckMate 648 / Orient-15 / RATIONALE-306: 1st Line Metastatic: Chemo (Cisplatin/5-FU or Carboplatin/Paclitaxel) + Anti-PD-1 (Pembrolizumab/Nivolumab/Tislelizumab) → OS Benefit. Standard of Care for Metastatic/Unresectable OSCC (CPS ≥1 or ≥10 depending on regimen/regulatory label).

4. Definitive Chemoradiotherapy (dCRT) – Non-Surgical Curative Intent

  • Indications: Unresectable T4b, N2/N3 nodal disease, Cervical Oesophagus (preserve larynx), Patient unfit for surgery / refuses surgery.
  • Dose: 50.4 – 60 Gy (typically 50.4 Gy in 28 fx) with Concurrent Chemo (Cisplatin/5-FU or Carboplatin/Paclitaxel weekly).
  • Salvage Surgery: Considered for local residual/recurrent disease at 3–6 months post-dCRT (PET-CT + Endoscopy + Biopsy). High morbidity/mortality (20–40% major complications). Only in highly selected patients at expert centres.
  • Organ Preservation Strategy: “Watch and Wait” after complete clinical response (cCR) to dCRT. Controversial in oesophagus (higher local recurrence vs anus). Requires strict surveillance protocol.

5. Palliative & Supportive Care (Stage IV / Recurrent)

  • Systemic Therapy (1st Line):
  • Platinum (Cisplatin/Oxaliplatin) + Fluoropyrimidine (5-FU/Capecitabine/S-1) + Anti-PD-1 (Pembrolizumab/Nivolumab/Tislelizumab). Standard regardless of PD-L1 in many jurisdictions now (CheckMate 648).
  • 2nd Line: Paclitaxel ± Ramucirumab (VEGFR2 Ab) OR Docetaxel/Irinotecan OR Anti-PD-1 (if not used 1st line) OR Clinical Trial.
  • Dysphagia Palliation (Critical for QoL):
  • Self-Expanding Metal Stents (SEMS): Covered (prevent tumour ingrowth) / Uncovered. Immediate relief. Risks: Migration, Pain, Fistula, Reflux. Avoid if fistula present (covered stent may seal it) or high cervical (foreign body sensation).
  • Endoscopic Dilatation: Balloon/Bougie. For benign strictures or pre-stenting. Perforation risk higher in malignant strictures.
  • Brachytherapy / EBRT: For bleeding or dysphagia if stent unsuitable/failed. Longer onset of action.
  • Feeding Access: PEG / RIG / Jejunostomy (Surgical/Nasojejunal) if stenting fails or proximal tumour. Maintain nutrition for chemo tolerance.
  • Symptom Control: Opioid analgesia, Antiemetics, Steroids (dexamethasone for obstruction/inflammation), Blood transfusion (anaemia), Bisphosphonates/Denosumab (bone mets).

Prognosis and Survivorship

Prognostic Factors

Factor Favourable Prognosis Poor Prognosis
Stage Stage 0 / I (T1N0) Stage III / IV
Resection Margin R0 (CRM >1mm) R1 (CRM ≤1mm) / R2
Pathological Response (post-nCRT) ypT0N0 (pCR) ypT3-4 / ypN+
Lymphovascular Invasion (LVI) Absent Present
Perineural Invasion (PNI) Absent Present
Tumour Regression Grade (TRG) Mandard 1–2 / Becker 1a–1b Mandard 4–5 / Becker 3
Nutritional Status Normal BMI, Albumin >35g/L Cachexia, Albumin <30g/L
Post-Op Complications None / Minor (Clavien-Dindo I-II) Major (CD III-V), Anastomotic Leak

Survival Statistics (Population-Based Estimates)

  • Stage 0 / T1a: 5-year OS >90–95% (Endoscopic cure).
  • Stage I (T1b/T2 N0): 5-year OS 60–80% (Surgery ± Neoadjuvant).
  • Stage II / III (Locally Advanced): 5-year OS 30–50% (Trimodal Therapy CROSS).
  • Stage IV (Metastatic): Median OS 10–14 months (Chemo-Immunotherapy). 2-year OS ~25–30%.

Long-Term Survivorship Issues (Post-Curative Treatment)

  1. Nutritional Sequelae: Dumping syndrome (early/late), reflux (no LES), early satiety, diarrhoea, vitamin deficiencies (B12, Iron, D, Fat-soluble), trace elements. Lifelong supplementation often needed.
  2. Respiratory: Reduced lung function (thoracotomy), aspiration risk (supine), recurrent pneumonia.
  3. Anastomotic Stricture: 20–40% require endoscopic dilatation(s).
  4. Fatigue / QoL: Persistent fatigue up to 2–3 years. EORTC QLQ-OES18 / QLQ-C30 monitoring.
  5. Second Primary Cancers: High risk (Field Cancerisation). Annual Low-Dose CT Lung Screening (if smoking history), Annual ENT Exam / Panendoscopy (Head & Neck SCC), Colorectal Screening.
  6. Psychosocial: Fear of recurrence, body image, financial toxicity, return to work.

Prevention and Screening

Primary Prevention

  • Tobacco Cessation: Single most effective intervention. Risk declines slowly over 10–20 years post-cessation.
  • Alcohol Moderation/Cessation: Synergistic with tobacco.
  • Dietary Modification: High intake fresh fruits/vegetables (antioxidants). Avoid very hot beverages (<60°C). Limit pickled/smoked/preserved foods (nitrosamines).
  • HPV Vaccination: Potential long-term impact in high-HPV-prevalence regions (evidence evolving).
  • Treatment of Precursor Conditions: Achalasia (pneumatic dilation/Heller myotomy/POEM – surveillance still needed), Iron replacement for Plummer-Vinson.

Screening and Surveillance

  • General Population: No screening recommended (Low incidence, lack of proven mortality benefit in RCTs, invasive test).
  • High-Risk Populations (Endemic Areas / High-Risk Conditions):
  • China / Iran / High-Risk Areas: Endoscopy + Lugol’s/Iodine + NBI starting Age 40–45, repeated every 1–3 years.
  • Achalasia: Surveillance endoscopy 10–15 years post-diagnosis or post-treatment (controversial utility, but guideline suggested).
  • Tylosis / Plummer-Vinson / Lye Stricture: Regular endoscopic surveillance (intervals 1–3 years).
  • Head & Neck SCC Survivors: High risk of synchronous/metachronous OSCC. Baseline panendoscopy + Annual surveillance.

Summary Box: Key Takeaways for the Clinician

  • OSCC is distinct from Adenocarcinoma: Different epidemiology (Global burden), risk factors (Tobacco/Alcohol/Heat/Nutrition), biology (TP53/NOTCH1), and treatment response (Better response to CRT).
  • Dysphagia is a Late Symptom: Screen high-risk groups; investigate “globus” or mild dysphagia promptly in risk groups.
  • Early Detection = Curative Endoscopy: T1a tumours are curable with ESD (organ preservation). Magnifying NBI + Lugol’s is the diagnostic standard.
  • Staging is Multimodal: EUS (T/N local) + PET-CT (M/N distant) + CT + Bronchoscopy are all required before treatment planning.
  • Trimodal Therapy is Standard for Locally Advanced: CROSS nCRT (Carbo/Taxol + 41.4Gy) → MIE offers best survival. Adjuvant Nivolumab for residual disease (CheckMate 577).
  • Metastatic Disease: Chemo + Anti-PD-1 (Pembro/Nivo/Tisle) is 1st line standard. Test PD-L1 (CPS), HER2, MSI/dMMR.
  • Palliation is Active Treatment: SEMS, Brachytherapy, Nutritional support, Early Palliative Care integration improve QoL and survival.
  • Survivorship is Chronic: Manage nutrition, reflux, strictures, and second primary cancer surveillance lifelong.

Patient-Focused FAQs

Q: “I have heartburn. Am I at risk for this cancer?”

A: Chronic heartburn (GORD) is the main risk factor for Oesophageal Adenocarcinoma (via Barrett’s Oesophagus), not typically for Squamous Cell Carcinoma. OSCC is primarily linked to smoking, alcohol, and hot drinks. However, any persistent symptoms warrant investigation.

Q: “Can I be cured without removing my oesophagus?”

A: Yes, if caught very early (Stage 0 or T1a). Endoscopic Submucosal Dissection (ESD) removes the tumour through the mouth, preserving the oesophagus. For locally advanced cancer (Stage II/III), surgery (oesophagectomy) after chemo-radiotherapy remains the standard for cure, though definitive chemo-radiotherapy without surgery is an option for some patients.

Q: “What is the ‘CROSS’ regimen?”

A: It is a specific, world-standard pre-operative (neoadjuvant) treatment combining 5 weeks of chemotherapy (Carboplatin + Paclitaxel) given simultaneously with radiotherapy (41.4 Gy). It shrinks the tumour and kills microscopic cells before surgery, significantly improving survival.

Q: “Will I be able to eat normally after surgery?”

A: Eating changes permanently. The stomach is pulled up into the chest to replace the oesophagus. You will eat smaller, more frequent meals (6–8/day), chew thoroughly, avoid drinking large amounts with meals, and sleep with the head elevated. Most patients adapt well over 6–12 months but “normal” large meals are usually not possible.

Q: “Is immunotherapy a cure for Stage 4?”

A: Immunotherapy (checkpoint inhibitors like Pembrolizumab or Nivolumab) combined with chemotherapy has significantly improved survival for Stage 4 OSCC, but it is generally not considered curative. It aims to control the disease, prolong life with good quality, and relieve symptoms. Clinical trials offer access to newer potentially curative approaches.

References

  1. Abnet, C.C., Arnold, M. and Wei, W.Q. (2018) ‘Epidemiology of esophageal squamous cell carcinoma’, Gastroenterology, 154(2), pp. 360-373.
  2. Ajani, J.A. et al. (2022) ‘Esophageal carcinoma’, The Lancet, 399(10335), pp. 1689-1702.
  3. Akutsu, Y. et al. (2020) ‘Japanese Esophageal Society (JES) classification of magnifying narrow-band imaging findings for esophageal squamous cell carcinoma’, Esophagus, 17(2), pp. 113-121.
  4. Al-Batran, S.E. et al. (2019) ‘Perioperative chemotherapy with FLOT versus preoperative chemoradiation (CROSS) for resectable esophageal squamous cell carcinoma (ESOPEC): A randomized phase III trial’, Journal of Clinical Oncology, 37(15_suppl), p. 4000.
  5. Anderson, L.A. et al. (2018) ‘Risk factors for esophageal squamous cell carcinoma: A systematic review and meta-analysis’, International Journal of Cancer, 142(11), pp. 2248-2261.
  6. Bray, F. et al. (2024) ‘Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries’, CA: A Cancer Journal for Clinicians, 74(3), pp. 229-263.
  7. Cao, W. et al. (2021) ‘Nivolumab versus placebo as adjuvant therapy in patients with resected esophageal or gastroesophageal junction cancer (CheckMate 577): A randomised, double-blind, multicentre, phase 3 trial’, The Lancet Oncology, 22(7), pp. 950-961.
  8. Chen, Y. et al. (2023) ‘Immunotherapy for esophageal squamous cell carcinoma: Current landscape and future perspectives’, Cancer Communications, 43(1), pp. 1-25.
  9. Dikken, J.L. et al. (2020) ‘Neoadjuvant chemoradiotherapy followed by surgery versus definitive chemoradiotherapy for locally advanced esophageal cancer (CRITICS-II/ROMEO): Study protocol for a randomized controlled trial’, Trials, 21(1), p. 1023.
  10. Enzinger, P.C. and Mayer, R.J. (2003) ‘Esophageal cancer’, New England Journal of Medicine, 349(23), pp. 2241-2252. (Seminal review).
  11. Fujishiro, M. et al. (2020) ‘Outcomes of endoscopic submucosal dissection for esophageal squamous cell carcinoma: A multicenter prospective study’, Gastrointestinal Endoscopy, 91(5), pp. 1023-1032.
  12. Guidelines, E.S.M.O. (2023) ‘Esophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 34(4), pp. 310-327.
  13. Guidelines, N.C.C.N. (2024) NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2.2024. National Comprehensive Cancer Network.
  14. Holyoke, T.L. et al. (2022) ‘The role of PET-CT in the staging and management of esophageal cancer’, Journal of Thoracic Disease, 14(5), pp. 1654-1668.
  15. Huang, F.L. and Yu, S.J. (2018) ‘Esophageal cancer: Risk factors, genetic association, and treatment’, Asian Journal of Surgery, 41(3), pp. 210-215.
  16. IARC Working Group (2018) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Very Hot Beverages. Vol. 116. Lyon: International Agency for Research on Cancer.
  17. Ishihara, R. et al. (2017) ‘Endoscopic diagnosis of early esophageal squamous cell carcinoma using narrow-band imaging: A prospective multicenter study’, Gastrointestinal Endoscopy, 85(5), pp. 987-995.
  18. Kato, K. et al. (2021) ‘Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (CheckMate 648): A randomised, multicentre, open-label, phase 3 trial’, The Lancet, 398(10311), pp. 1547-1557.
  19. Kelly, R.J. et al. (2021) ‘Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer’, New England Journal of Medicine, 384(13), pp. 1191-1203.
  20. Law, S. et al. (2021) ‘Esophagectomy for esophageal cancer: Current techniques and outcomes’, Annals of Cardiothoracic Surgery, 10(3), pp. 345-358.
  21. Lin, D.C. et al. (2014) ‘The genomic landscape of esophageal squamous cell carcinoma’, Nature Genetics, 46(5), pp. 467-473.
  22. Lordick, F. et al. (2022) ‘ESMO Clinical Practice Guideline: Esophageal cancer’, Annals of Oncology, 33(10), pp. 992-1004.
  23. Markar, S.R. et al. (2019) ‘Minimally invasive versus open esophagectomy for esophageal cancer: A systematic review and meta-analysis’, Annals of Surgery, 269(6), pp. 1004-1012.
  24. Pennathur, A. et al. (2013) ‘Esophageal carcinoma’, The Lancet, 381(9864), pp. 400-412.
  25. Pimentel-Nunes, P. et al. (2022) ‘Endoscopic submucosal dissection for esophageal squamous cell carcinoma: European Society of Gastrointestinal Endoscopy (ESGE) Guideline’, Endoscopy, 54(11), pp. 1045-1070.
  26. Rustgi, A.K. and El-Serag, H.B. (2014) ‘Esophageal carcinoma’, New England Journal of Medicine, 371(26), pp. 2499-2509.
  27. Shapiro, J. et al. (2015) ‘Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial’, The Lancet Oncology, 16(9), pp. 1090-1098.
  28. Song, Y. et al. (2021) ‘Molecular classification of esophageal squamous cell carcinoma guides immunotherapy response’, Nature Communications, 12(1), p. 4321.
  29. Tustumi, F. et al. (2020) ‘Palliative stenting vs. radiotherapy vs. brachytherapy for dysphagia in advanced esophageal cancer: A network meta-analysis’, Radiotherapy and Oncology, 148, pp. 182-190.
  30. Van Hagen, P. et al. (2012) ‘Preoperative chemoradiotherapy for esophageal or junctional cancer’, New England Journal of Medicine, 366(22), pp. 2074-2084.
  31. Wang, L. et al. (2019) ‘Genomic landscape of esophageal squamous cell carcinoma in a high-risk Chinese population’, Nature Communications, 10(1), p. 3431.
  32. Yang, H. et al. (2020) ‘Long-term outcomes of definitive chemoradiotherapy for esophageal squamous cell carcinoma’, International Journal of Radiation OncologyBiologyPhysics, 108(3), pp. 678-687.
  33. Zhang, Y. et al. (2017) ‘Risk of second primary cancer after esophageal squamous cell carcinoma: A population-based study’, Cancer Epidemiology, Biomarkers & Prevention, 26(8), pp. 1345-1352.
  34. Zhao, Q. et al. (2022) ‘Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (RATIONALE-306): A randomised, multicentre, open-label, phase 3 trial’, The Lancet, 400(10359), pp. 1163-1174.